Peptides for Weight Loss: What Should Women Know Before Getting Started?

The first thing I want you to know is that you are not behind for asking. Somewhere after thirty, your body changes the rules. I teach women the new ones, and right now one of the new ones is that a medication can be part of the conversation.

The second thing is that this is a big decision, and the internet is not being honest with you about it. So here is the plain version, with the sources linked where the claims are.

What are weight-loss peptides, and are they the same thing as GLP-1 medications?

A peptide is a short chain of amino acids, the same building blocks that make up protein. Your body makes thousands of them. Insulin is a peptide. So is the gut hormone GLP-1, which your intestine releases after you eat.

"Peptides" is a broad term. Not every peptide has the same purpose, evidence, safety profile, or regulatory status. Choosing one because it is trending online is not a plan.

When the conversation is about weight, though, the word almost always points at one drug class: GLP-1 receptor agonists. Semaglutide (sold as Wegovy for weight, Ozempic for type 2 diabetes) is one. Tirzepatide (Zepbound for weight, Mounjaro for type 2 diabetes) is the other, and it also acts on a second gut hormone called GIP, according to the SURMOUNT-1 trial report in the New England Journal of Medicine.

According to Mayo Clinic, these medications "mimic the way a hormone called glucagon-like peptide 1 works in the body." They prompt insulin when blood sugar rises, they appear to curb hunger, and they slow the movement of food from the stomach into the small intestine, so you feel full faster and longer.

In plain words: the medication turns the volume down on hunger. It does not change what you eat, how you train, or how you sleep. That part is still yours.

So when I say GLP-1 medication and you say peptide, we are talking about the same thing. I will use both words in this article because women arrive using both.

How are these different from the diet pills I remember?

Most of us over 35 remember a diet pill era. A friend took something that made her jittery, she lost weight fast, and it came back the moment she stopped. That memory is fair, and it is worth separating from what is happening now.

Three things are genuinely different about this class.

First, the evidence. Semaglutide was studied in a 68 week, placebo controlled trial of 1,961 adults (STEP 1). Tirzepatide was studied in a 72 week trial of 2,539 adults (SURMOUNT-1). Those are long, large, published trials, not a supplement label.

Second, the mechanism. These copy a hormone your gut already makes, per Mayo Clinic, rather than acting as a stimulant. That is why the main side effects are digestive, not a racing heart, although the Wegovy label does list heart rate increase among its warnings.

Third, the framing. Both FDA labels describe the drug as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management (Wegovy label above; Zepbound label). Chronic is the word to notice. The FDA is treating this as long-term management of a long-term condition, not a six week reset.

Here is where I stand. Most programs focus on restriction. I don't. A medication that quiets hunger is not a restriction plan, but it can turn into one if nobody is paying attention to what you are actually eating. I will come back to that.

Who should not use them, and what are the risks?

This section comes straight from the prescribing information, because that is the only honest place to get it. I am a coach. I do not decide who is a candidate. Your prescriber does.

Both Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors seen in rodents. The labels state it is unknown whether the drugs cause these tumors in humans, and both are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both are also contraindicated after a serious allergic reaction to the drug or its ingredients (Wegovy label; Zepbound label).

The warnings and precautions on the labels include acute pancreatitis, acute gallbladder disease, low blood sugar (especially alongside diabetes medications), acute kidney injury from dehydration, severe gastrointestinal reactions, allergic reactions, complications of diabetic retinopathy, and a risk of stomach contents entering the lungs during general anesthesia or deep sedation. The Wegovy label adds heart rate increase. The Zepbound label adds suicidal behavior and ideation.

The Zepbound label also says it should not be combined with other tirzepatide products or any GLP-1 receptor agonist, and that it has not been studied in people with a history of pancreatitis.

The common side effects are the ones you have heard about: nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion, each reported in at least five percent of people on the labels. The Wegovy label also lists fatigue, headache, dizziness, reflux, and hair loss among its common reactions. In STEP 1, nausea and diarrhea were typically transient and mild to moderate, and 4.5 percent of the semaglutide group stopped because of gastrointestinal events.

Now the part that belongs to you and your prescriber, not to me: your full medical history, every medication and supplement you take, whether you are pregnant, planning a pregnancy, or breastfeeding, any history of pancreatitis, gallbladder disease, kidney problems, eating disorders, or depression, and any surgery on the calendar. If any of those apply, say so out loud at the appointment. Nothing on this page replaces that conversation.

What results are realistic in the first three to six months?

The honest answer is: probably less than the headline number, and that is by design.

Both medications start at a low dose and step up roughly every four weeks. Wegovy begins at 0.25 mg weekly and climbs over four months toward a maintenance dose (Wegovy label). Zepbound begins at 2.5 mg weekly and increases in 2.5 mg steps at least four weeks apart, to a maximum of 15 mg (Zepbound label). In SURMOUNT-1, the dose escalation period alone was 20 weeks.

So your first three to six months are mostly the ramp. Appetite quiets gradually. Side effects tend to cluster in this window, because in both trials gastrointestinal events occurred primarily during dose escalation.

The numbers everyone quotes come from the end of the trials, not from month three. In STEP 1, the semaglutide group averaged 14.9 percent body weight lost at 68 weeks against 2.4 percent for placebo, and 86.4 percent of the semaglutide group lost at least five percent. In SURMOUNT-1, the tirzepatide groups averaged 15.0, 19.5, and 20.9 percent at 72 weeks on the 5, 10, and 15 mg doses, against 3.1 percent for placebo.

Those are trial averages from people who also got a lifestyle intervention, not promises to you. An average hides a wide spread. Some women in those trials lost far more, and some lost little.

I want to name what nobody puts on the ad. The trial participants were counseled on food and activity the entire time. The label says the drug is an adjunct to diet and activity. Take away the diet and the activity and you are running an experiment nobody has published.

This is never required, and not where we start. But for the right person, it can be a game changer, offered as a tool, never a shortcut.

Do I need a prescription, and how does oversight work?

Yes. Semaglutide and tirzepatide are prescription drugs. Anything sold to you without a prescription and a licensed pharmacy behind it is not the same product, no matter what the website says.

That brings up the compounded question, because it is the one I get asked most. Compounded versions are made by pharmacies rather than the drug's manufacturer, usually at a lower price. The FDA has been clear about where they stand: "Compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."

On that same page the FDA describes adverse event reports tied to dosing errors, some requiring hospitalization, and says that as of May 31, 2026 it had received 990 reports for compounded semaglutide and over 730 for compounded tirzepatide, with actual numbers likely higher. It also warns that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than the approved drugs use.

The FDA's advice to patients is simple: get the prescription from a licensed clinician and fill it at a state licensed pharmacy.

Here is how it works around my coaching, in the only words I use for it. Peptide and metabolic support is offered through a licensed medical team. It is never required, and it is not where anyone starts. The medical team evaluates eligibility and prescribes if appropriate. I coach the food, the training, and the habits alongside. I do not prescribe, choose a dose, change a medication, or read your labs. You can read more about how that line is drawn on the page about GLP-1 coaching alongside a licensed medical team and on the team page.

Whoever you see, in my program or anywhere else, ask questions. Good care shouldn't end after the prescription. These are the ones I would want answered before I signed anything.

Why do nutrition, protein, and strength training still matter if the medication handles appetite?

One of the biggest misconceptions about these medications is that they eliminate the need to pay attention to nutrition and training.

They don't.

Think about what the drug actually does. It quiets hunger, so you eat less. That is the whole mechanism. It has no opinion about whether the smaller amount you eat contains enough protein to hold on to your muscle, or whether you lifted anything heavier than a laptop this week.

When hunger is low, the easy path is to skip meals and coast. For a few months the scale rewards that. Then energy drops, workouts feel flat, hair sheds, and the weight that came off was not all fat. I wrote a full article on this: why muscle loss happens on semaglutide and what to do about it.

The trials themselves were built with a lifestyle intervention running the whole time. In STEP 1 it was written into the design: semaglutide "plus lifestyle intervention." The labels say the same. Diet and activity are not the optional add-on. The drug is the add-on.

So in my program, medication or not, the priorities do not move. Protein first at every meal, because a smaller appetite means every bite has to do more work. Strength training two to four days a week, because muscle is the thing you cannot buy back later. Food you can actually eat, on a Tuesday, in your real life, because a plan built on nausea-week salads does not survive month five.

If you want a starting number for protein, use the protein calculator. It gives you a range to bring to your prescriber and your coach, not a prescription.

Across 470+ clients, the pattern that holds weight off is the same with or without medication: enough food, enough protein, progressive strength work, and a plan that bends around a real life instead of breaking.

What happens when I stop?

This is the question I wish more women asked before they started, so let me give you the data.

The STEP 1 trial extension followed 327 participants for a year after semaglutide and the lifestyle program were both stopped at week 68. The semaglutide group had lost an average of 17.3 percent of body weight on treatment. One year off treatment they had regained 11.6 percentage points of it, for a net loss of 5.6 percent from where they started. Most of the cardiometabolic improvements drifted back toward baseline too. The authors' conclusion was that participants regained about two-thirds of their prior weight loss and that ongoing treatment appears to be required to maintain the improvements.

Read that once more. Two-thirds back within a year, in a group that also stopped their lifestyle program.

I know this cycle personally, without any medication involved. For years I tried every diet, started over, and watched the weight come back. I could lose it, I just couldn't keep it off. What finally broke that pattern was not a stronger tool. It was learning to eat and train in a way I could keep doing when nobody was watching.

That is why I care so much about what you build while the medication is doing the appetite work. The habits are the thing you get to keep. Whether you stay on the medication long term, taper, or stop is a decision for you and your prescriber. What you can do while you decide is make sure that if the volume comes back up on hunger, there is a woman standing there who already knows how to eat.

So what should I actually do next?

If you are early in this, do three things in this order.

Read the label for whichever medication you are considering. The Wegovy and Zepbound prescribing information are public documents, linked above, and the patient sections are written for you. Ten minutes with the real document beats ten hours of forum threads.

Write down your questions and your history. Use the checklist above. Bring it to a licensed clinician who will actually monitor you after the first prescription.

Then decide what you are going to build alongside it. Protein, strength, sleep, and a food pattern that survives your actual week. That part does not need a prescription, and it is where every woman in my program starts, medication or not.

If you want to talk through whether metabolic support fits your situation, the assessment is the door. It is a conversation, not a commitment. Take your time. There's zero pressure or rushed sales tactics.